Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) announced preclinical results for selective KAT6A protein degraders in estrogen receptor-positive, HER2-negative breast cancer models.
All four compounds, OP-1 through OP-4, produced near-complete degradation of KAT6A with minimal effects on other targets. The compounds inhibited cancer cell proliferation, and activity was observed in models with both mutant and wild-type (nonmutated) ESR1. Used alone, the degraders caused tumor regression in T47D and slowed tumor growth in MCF7 and ST941. They were well tolerated across all groups in studies using implanted tumors.
The compounds were absorbed after oral dosing in preclinical studies, which Olema said suggests the potential for once-daily dosing in humans. The findings are scheduled for a poster presentation on November 18, 2026, at the EORTC-NCI-AACR Symposium in Barcelona.
Positive
- Minor pointOP-1 through OP-4 produced tumor regression as single agents in the T47D breast cancer model
- Minor pointAll four degraders inhibited tumor growth in the MCF7 and ST941 breast cancer models
- Minor pointCell proliferation fell across multiple ER+/HER2- breast cancer models, with activity in mutant and wild-type ESR1 models
- Minor pointAll four compounds produced near-complete KAT6A degradation with minimal effects on other targets
- Minor pointH3K23Ac and estrogen receptor alpha levels fell in preclinical testing, with better responses observed than with prifetrastat
2 minor points
- Minor pointAll four degraders were well tolerated across all study groups in models with implanted tumors
- Minor point. Forward-looking: it has not happened yet and may not happen.Oral absorption in preclinical studies suggests potential for once-daily dosing in humans, Olema said
Negative
- None.
Key Figures
- Degraders evaluated
- Four
- Preclinical models
Key Terms
pharmacokinetics medical
orthosteric inhibitor medical
proteasome-dependent medical
xenograft medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Orally bioavailable KAT6A degraders demonstrated potent antiproliferative activity in diverse in vivo models of ER+/HER2- breast cancer
- KAT6A degradation was active in both ESR1-mutant and wild-type cell models
- Degraders were well-tolerated in all groups
SAN FRANCISCO, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preclinical data on a series of selective KAT6A degraders in estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer models. The findings will be presented in a poster session at the 38th EORTC-NCI-AACR (ENA) Symposium, held November 18-20, 2026 in Barcelona, Spain.
“We are encouraged by these preclinical findings that support the potential of our highly potent and specific KAT6A degraders as a new therapeutic approach for patients with ER+/HER2- breast cancer,” said David C. Myles, Ph.D., Chief Scientific Officer of Olema Oncology. “Taken together with favorable pharmacokinetics and oral bioavailability, the robust antitumor activity observed across both ESR1-mutant and wild-type in vivo models demonstrates their broad potential. We look forward to the further evaluation of these KAT6A degraders as we explore broadening our pipeline of novel therapies for breast cancer and beyond to complement our KAT6 inhibitor, OP-3136.”
KAT6A and KAT6B are distinct components of an epigenetic regulatory complex that controls transcription. Higher KAT6A expression is associated with poorer outcomes in ER+/HER2- breast cancer. Targeted degradation may eliminate KAT6A's scaffolding functions and transcriptional activity. Four bifunctional small-molecule degraders, OP-1 through OP-4, were evaluated in preclinical models measuring in vitro degradation, selectivity, proliferation, and transcriptional analyses with in vivo xenograft studies.
Key Findings
Selective protein degradation is a novel and effective approach to targeting the KAT6 epigenetic regulatory complex. All four degraders:
- Demonstrated potent and near-complete proteasome-dependent degradation of only KAT6A with minimal effect on off-target substrates.
- Caused substantial inhibition of cell proliferation across a diverse range of ER+/HER2- breast cancer models and demonstrated on-target down-regulation of H3K23Ac and ER-alpha protein levels, with superior responses observed compared to the orthosteric inhibitor, prifetrastat.
- Produced tumor regression as monotherapy in the T47D model and significant tumor growth inhibition in the MCF7 and ST941 models.
- Were well-tolerated in the xenograft studies across all groups.
- Showed good oral bioavailability, suggesting the potential of once-daily oral dosing in humans.
Poster Presentation Details
- Title: Selective Degradation of KAT6A Suppresses ERα Signaling and Tumor Growth in ER+ Breast Cancer Models
- Abstract Number: 120
- Session: PP18
- Date: Wednesday, November 18, 2026
Additional information can be found on the ENA website, including abstracts. A copy of the poster will be made available on the Publications page of Olema’s website in alignment with the ENA 2026 embargo policy.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in South San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “anticipate,” “believe,” “could,” “expect,” “goal,” “intend,” “may,” “on track,” “potential,” “upcoming,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the potential value, beneficial characteristics, and therapeutic effects of Olema’s KAT6A degraders; the potential for KAT6A degraders to serve as a novel therapeutic approach for patients with ER+/HER2- breast cancer; the extent to which preclinical findings may translate into clinical efficacy or therapeutic benefit; the continued evaluation and development of Olema’s KAT6A degraders; and the potential for these degraders to expand Olema’s early-stage pipeline and complement OP-3136 in breast cancer and other indications. Because such statements deal with future events and are based on Olema’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, those discussed in the section titled “Risk Factors” in Olema’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and future filings and reports that Olema makes from time to time with the U.S. Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements, including in the event that actual results differ materially from those anticipated in the forward-looking statements.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications and Investor Relations
Olema Oncology
media@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Olema Oncology’s KAT6A degraders do in preclinical breast cancer models?
All four degraders caused tumor regression in T47D when used alone and inhibited tumor growth in MCF7 and ST941. The compounds were well tolerated across all groups in studies using implanted tumors.
Did Olema Oncology’s KAT6A degraders show activity in ESR1-mutant breast cancer models?
Yes. The degraders showed activity in breast cancer models with both mutant and wild-type ESR1. These were preclinical findings.